Yahoo
Toronto - Delayed Quote CAD

Resverlogix Corp. (RVX.TO)

0.0750 0.0000 (0.00%)
At close: November 2 at 3:47:44 PM EST
Chart Range Bar
Loading chart for RVX.TO
  • Previous Close 0.0750
  • Open 0.0750
  • Bid 0.0750 x --
  • Ask 0.0800 x --
  • Day's Range 0.0750 - 0.0750
  • 52 Week Range 0.0750 - 0.1500
  • Volume 4,000
  • Avg. Volume 24,209
  • Market Cap (intraday) 25.822M
  • Beta (5Y Monthly) 0.96
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0400
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.

www.resverlogix.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

RVX.TO
25.00%
S&P/TSX Composite index (^GSPTSE)
12.35%

1-Year Return

RVX.TO
25.00%
S&P/TSX Composite index (^GSPTSE)
18.31%

3-Year Return

RVX.TO
6.25%
S&P/TSX Composite index (^GSPTSE)
82.41%

5-Year Return

RVX.TO
86.61%
S&P/TSX Composite index (^GSPTSE)
69.11%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -40.29%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -10.69M

  • Diluted EPS (ttm)

    -0.0400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    80k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -4.24M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: